The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Advances in KRAS G12D-targeted therapy for pancreatic cancer
Wungki Park, MD, MS, Memorial Sloan Kettering Cancer Center, New York, NY, describes ongoing advancements in targeted therapy for KRAS G12D mutations, a key driver in pancreatic cancer. It highlights the novel mechanism of ASP3082, a protein degrader targeting KRAS G12D via intracellular proteasome pathways. With active development and competition in this field, there is optimism for safer, effective therapies to improve outcomes in pancreatic cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
